• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于体外循环冠状动脉旁路移植术期间抗血栓药物清除的新型血浆分离设备。

A New Apheresis Device for Antithrombotic Drug Removal during Off-Pump Coronary Artery Bypass Surgery.

机构信息

Department of Cardiac Surgery, Artemed Klinikum München Süd, 81379 Munich, Germany.

Department of Cardiac Surgery, Paracelsus Medical University, 40791 Nuremberg, Germany.

出版信息

Medicina (Kaunas). 2022 Oct 10;58(10):1427. doi: 10.3390/medicina58101427.

DOI:10.3390/medicina58101427
PMID:36295587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9609020/
Abstract

: The hemoadsorption device CytoSorb (CytoSorbents Inc., Princeton, NJ, USA) has been shown to efficiently remove ticagrelor from whole blood in vitro. A promising clinical experience was made with the integration of the hemoadsorption cartridge on the cardiopulmonary bypass (CPB) circuit during cardiac surgery to reduce adverse events. : In this report, we describe a novel approach using a new apheresis platform, PUR-01 (Nikkisio Co., Ltd., Tokyo, Japan), which was used as the extracorporeal circuit where CytoSorb could be installed for the removal of ticagrelor during off-pump coronary artery bypass (OPCAB) procedures. : In a 74-year-old male (index case) with coronary artery disease and dual antiplatelet therapy, hemoadsorption was initiated with a skin incision for OPCAB surgery and was continued for 221 min to eliminate ticagrelor. The blood volume that had circulated through the CytoSorb was 39.04 L in total. Thus far, this treatment strategy has been used in four cases with CHD and DAPT who needed OPCAB surgery. The intraoperative and postoperative courses were uneventful in all patients. No device-related adverse events occurred. : The combination of the PUR-01 apheresis pump and hemoadsorption with the CytoSorb column during OPCAB procedures appears to be safe and effective in eliminating antiplatelet drugs.

摘要

: 体外研究表明,血液吸附装置 CytoSorb(CytoSorbents Inc.,新泽西州普林斯顿)能够有效清除全血中的替格瑞洛。在心脏手术中,将血液吸附柱整合到体外循环(CPB)回路中以减少不良事件,这一临床应用经验令人充满希望。: 在本报告中,我们描述了一种新的方法,使用新型血浆分离平台 PUR-01(日本日机装株式会社)作为体外回路,可在非体外循环冠状动脉旁路移植术(OPCAB)期间安装 CytoSorb 以清除替格瑞洛。: 在一位 74 岁男性(首发病例)冠心病合并双联抗血小板治疗患者中,在切开皮肤进行 OPCAB 手术时开始进行血液吸附,持续 221 分钟以清除替格瑞洛。总共循环通过 CytoSorb 的血液量为 39.04 L。迄今为止,该治疗策略已用于 4 例需要 OPCAB 手术的 CHD 和 DAPT 患者。所有患者的术中及术后过程均顺利,无与器械相关的不良事件发生。: 在 OPCAB 手术期间,将 PUR-01 血浆分离泵与 CytoSorb 柱结合进行血液吸附,似乎在消除抗血小板药物方面是安全且有效的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/682eab928894/medicina-58-01427-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/78fe89715ec3/medicina-58-01427-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/a6b919430e9e/medicina-58-01427-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/16534220c7da/medicina-58-01427-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/682eab928894/medicina-58-01427-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/78fe89715ec3/medicina-58-01427-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/a6b919430e9e/medicina-58-01427-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/16534220c7da/medicina-58-01427-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0f/9609020/682eab928894/medicina-58-01427-g004.jpg

相似文献

1
A New Apheresis Device for Antithrombotic Drug Removal during Off-Pump Coronary Artery Bypass Surgery.一种用于体外循环冠状动脉旁路移植术期间抗血栓药物清除的新型血浆分离设备。
Medicina (Kaunas). 2022 Oct 10;58(10):1427. doi: 10.3390/medicina58101427.
2
Antithrombotic drug removal with hemoadsorption during off-pump coronary artery bypass grafting.体外循环冠状动脉旁路移植术中应用血液吸附去除抗血栓药物。
J Cardiothorac Surg. 2024 Apr 18;19(1):246. doi: 10.1186/s13019-024-02772-1.
3
Ticagrelor and Rivaroxaban Elimination With CytoSorb Adsorber Before Urgent Off-Pump Coronary Bypass.在紧急不停跳冠状动脉旁路移植术前行 CytoSorb 吸附剂清除替格瑞洛和利伐沙班。
Ann Thorac Surg. 2020 Nov;110(5):e369-e370. doi: 10.1016/j.athoracsur.2020.03.108. Epub 2020 May 11.
4
Intraoperative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting.体外循环冠状动脉搭桥术中通过血液吸附术去除术中替格瑞洛
JTCVS Open. 2023 May 6;15:190-196. doi: 10.1016/j.xjon.2023.04.013. eCollection 2023 Sep.
5
Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.微创和传统心胸外科手术中血液管理的药物、器械、技术与方法:国际微创心胸外科协会(ISMICS)2011年共识声明
Innovations (Phila). 2012 Jul-Aug;7(4):229-41. doi: 10.1097/IMI.0b013e3182747699.
6
Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?体外循环是冠状动脉旁路移植术后阿司匹林抵抗的一个原因吗?
Eur J Cardiothorac Surg. 2005 Apr;27(4):606-10. doi: 10.1016/j.ejcts.2004.12.010. Epub 2005 Jan 19.
7
Is administration of dual-antiplatelet therapy beneficial for patients following off-pump coronary artery bypass grafting?双抗血小板治疗对非体外循环冠状动脉搭桥术后患者有益吗?
Interact Cardiovasc Thorac Surg. 2018 Oct 1;27(4):548-554. doi: 10.1093/icvts/ivy113.
8
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.非体外循环冠状动脉旁路移植术后氯吡格雷与替格瑞洛的随机试验。
Ann Thorac Surg. 2023 May;115(5):1127-1134. doi: 10.1016/j.athoracsur.2022.10.040. Epub 2022 Nov 14.
9
Comparison of minimally invasive closed circuit extracorporeal circulation with conventional cardiopulmonary bypass and with off-pump technique in CABG patients: selected parameters of coagulation and inflammatory system.冠状动脉旁路移植术(CABG)患者中微创闭合式体外循环与传统心肺转流及非体外循环技术的比较:凝血和炎症系统的选定参数
Eur J Cardiothorac Surg. 2005 Jul;28(1):127-32. doi: 10.1016/j.ejcts.2005.03.032.
10
Use of CytoSorb® hemoadsorption column during prolonged cardiopulmonary bypass in complex cardiac surgery patient.在复杂心脏手术患者长时间体外循环期间使用 CytoSorb® 血液吸附柱。
J Cardiothorac Surg. 2022 Jul 7;17(1):172. doi: 10.1186/s13019-022-01922-7.

引用本文的文献

1
Potential Clinical Use of CytoSorb for Ticagrelor and Rivaroxaban Elimination Prior to Emergency Orthopedic Surgery in Trauma Patients.CytoSorb在创伤患者急诊骨科手术前清除替格瑞洛和利伐沙班的潜在临床应用
Life (Basel). 2025 Jul 3;15(7):1065. doi: 10.3390/life15071065.
2
Intraoperative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting.体外循环冠状动脉搭桥术中通过血液吸附术去除术中替格瑞洛
JTCVS Open. 2023 May 6;15:190-196. doi: 10.1016/j.xjon.2023.04.013. eCollection 2023 Sep.

本文引用的文献

1
Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review.接受心脏手术的抗血栓药物治疗患者围手术期出血风险的管理——一项系统综述
J Thorac Dis. 2022 Aug;14(8):3030-3044. doi: 10.21037/jtd-22-428.
2
Comparison of the CytoSorb 300 mL and Jafron HA380 hemoadsorption devices: an study.CytoSorb 300ml 与 Jafron HA380 两款血液吸附器的比较:一项研究。
Minim Invasive Ther Allied Technol. 2022 Oct;31(7):1058-1065. doi: 10.1080/13645706.2022.2104617. Epub 2022 Aug 1.
3
Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent.
使用多孔聚合物珠吸附剂从全血中去除抗血栓药物。
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):847-856. doi: 10.1093/ehjcvp/pvac036.
4
Hemadsorption for removal of ticagrelor and direct oral anticoagulants in cardiac surgery.血液吸附去除心脏手术中的替格瑞洛和直接口服抗凝剂。
Expert Rev Cardiovasc Ther. 2022 Feb;20(2):141-150. doi: 10.1080/14779072.2022.2044306. Epub 2022 Feb 28.
5
Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations.急性 A 型主动脉夹层手术期间利伐沙班和替格瑞洛的血液吸附。
Ann Thorac Cardiovasc Surg. 2022 Jun 20;28(3):186-192. doi: 10.5761/atcs.oa.21-00154. Epub 2022 Jan 20.
6
Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study.采用细胞因子吸附剂和白蛋白透析成功清除急性肝功能障碍危重症患者胆红素:一项初步研究。
Sci Rep. 2021 May 13;11(1):10190. doi: 10.1038/s41598-021-89712-4.
7
Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis.血液净化用细胞因子吸附剂清除危重症横纹肌溶解症患者肌红蛋白。
Crit Care. 2021 Jan 28;25(1):41. doi: 10.1186/s13054-021-03468-x.
8
Ticagrelor and Rivaroxaban Elimination With CytoSorb Adsorber Before Urgent Off-Pump Coronary Bypass.在紧急不停跳冠状动脉旁路移植术前行 CytoSorb 吸附剂清除替格瑞洛和利伐沙班。
Ann Thorac Surg. 2020 Nov;110(5):e369-e370. doi: 10.1016/j.athoracsur.2020.03.108. Epub 2020 May 11.
9
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.经皮冠状动脉介入治疗后出血风险、双联抗血小板治疗停药和不良事件:PARIS 注册研究。
Circ Cardiovasc Interv. 2020 Apr;13(4):e008226. doi: 10.1161/CIRCINTERVENTIONS.119.008226. Epub 2020 Mar 27.
10
Hemoadsorption to Reduce Plasma-Free Hemoglobin During Cardiac Surgery: Results of REFRESH I Pilot Study.心脏手术中应用血液吸附降低血浆游离血红蛋白:REFRESH I 研究的初步结果。
Semin Thorac Cardiovasc Surg. 2019 Winter;31(4):783-793. doi: 10.1053/j.semtcvs.2019.05.006. Epub 2019 May 11.